Amgen VP of R&D David Reese

Am­gen rolls out da­ta for KRAS in­hibitor com­bo study in col­orec­tal can­cer, hop­ing to move on from ug­ly ear­ly re­sults

With the first win for its KRAS in­hibitor so­tora­sib in hand, Am­gen is push­ing ahead with an ag­gres­sive clin­i­cal plan to cap­i­tal­ize on its first-to-mar­ket stand­ing. The drug­mak­er thinks com­bi­na­tions — in-house or oth­er­wise — could of­fer a path for­ward, and one ear­ly read­out from that strat­e­gy is bear­ing fruit.

A com­bi­na­tion of Am­gen’s so­tora­sib and its EGFR in­hibitor Vectibix post­ed an over­all re­sponse rate of 27% in 26 pa­tients with ad­vanced col­orec­tal can­cer (CRC) with the KRAS-G12C mu­ta­tion, ac­cord­ing to da­ta from the larg­er Phase Ib/II CODE­BREAK 101 study set to present at this week­end’s vir­tu­al ES­MO Con­gress.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.